

**PB 38 of 2024**

National Health (April 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024

*National Health Act 1953*

I, Nikolai Tsyganov, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care make this determination under subsection 99ADHB(6) of the *National Health Act 1953*.

Dated  27 March 2024

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

1 Name of Determination

(1) This instrument is the *National Health (April 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024*.

(2) This instrument may also be cited as PB 38 of 2024.

2 Commencement

This instrument commences the day after registration.

3 Definition

Note: A number of expressions used in this instrument are defined in Part VII the Act,

In this instrument:

***Act*** means the *National Health Act 1953*.

4 Authority

This instrument is made under subsection 99ADHB(6) of the Act.

5 Brand of pharmaceutical item with approved ex-manufacturer price not reduced

I determine under subsection 99ADHB(6) of the Act that, for the purposes of subsection 99ADHB(2), the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 in the table in Schedule 1 is not reduced on 1 April 2024.

Schedule 1— Brand of pharmaceutical item with approved ex-manufacturer price not reduced

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Column 1** | **Column 2** | | | |
| **Item** | **Brand of Pharmaceutical Item** | | | |
|  | **Drug** | **Form** | **Manner of administration** | **Brand** |
| 1 | Fosnetupitant with palonosetron | Solution concentrate for I.V. infusion containing fosnetupitant 235 mg (as chloride hydrochloride) and palonosetron 250 microgram (as hydrochloride) | Injection | Akynzeo IV |
| 2 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/10/12.5 |
| 3 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Olmekar HCT 40/10/12.5 |
| 4 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Olamlo HCT 40/10/12.5 |
| 5 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 |
| 6 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/10/25 |
| 7 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Olamlo HCT 40/10/25 |
| 8 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Olmekar HCT 40/10/25 |
| 9 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/10/25 |
| 10 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/5/12.5 tablet |
| 11 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Olamlo HCT 40/5/12.5 |
| 12 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Olmekar HCT 40/5/12.5 |
| 13 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/5/12.5 |
| 14 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/5/25 tablet |
| 15 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Olamlo HCT 40/5/25 |
| 16 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Olmekar HCT 40/5/25 |
| 17 | Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 |
| 18 | Sitagliptin with metformin | Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Janumet XR |
| 19 | Sitagliptin with metformin | Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Sitagliptin/Metformin Sandoz XR |
| 20 | Sitagliptin with metformin | Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Janumet XR |
| 21 | Sitagliptin with metformin | Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Sitagliptin/Metformin Sandoz XR |